Abstract:Tenacissoside H (TDH) is a monomer extracted from Marsdenia tenacissma and has been shown to be anti‐inflammatory and antioxidant. However, the role of TDH in skeletal diseases remains unclear. In this study, TDH was found to inhibit the IKK/NF‐κB signalling pathway, down‐regulate the expression of c‐FOS, NFATc1, CTSK, and ATP6v0d2, and suppress osteoclast differentiation and function. And TDH could inhibit lipopolysaccharide‐induced transcription of Il1‐β, Il‐6 and Tnf‐α, down‐regulate ROS levels, and In addition, in vivo studies showed that TDH significantly repaired LPS‐induced bone loss. TDH has clinical promise for antiosteoclast activity. Periodontal disease and arthroplasty prosthesis loosening and destabilization are both associated with osteolysis, which is predominantly caused by abnormal bone resorption triggered by pro‐inflammatory cytokines. Osteoclasts (OCs) are critical players in the process. Concerns regarding the long‐term efficacy and side effects of current frontline therapies, however, remain. Alternative therapies are still required. The aim of this work was to investigate the involvement of Tenacissoside H (TDH) in RANKL‐mediated OC differentiation, as well as inflammatory osteolysis and associated processes. In vitro, bone marrow‐derived macrophages (BMMs) cultured with RANKL and M‐CSF were used to detect TDH in the differentiation and function of OCs. Real‐time quantitative PCR was used to measure the expression of specific genes and inflammatory factors in OCs. Western blot was used to identify NFATc1, IKK, NF‐κB, MAPK pathway, and oxidative stress‐related components. Finally, an LPS‐mediated calvarial osteolysis mouse model was employed to explore TDH's role in inflammatory osteolysis. The results showed that in vivo TDH inhibited the differentiation and resorption functions of OCs and down‐regulated the transcription of osteoclast‐specific genes, as well as Il‐1β, Il‐6 and Tnf‐α. In addition, TDH inhibited the IKK and NF‐κB signalling pathways and down‐regulated the level of ROS. In vivo studies revealed that TDH improves the bone loss caused by LPS. TDH may be a new candidate or treatment for osteoclast‐associated inflammatory osteolytic disease.

Forsythoside A Inhibits Osteoclast Genesis and Bone Resorption via Suppressing NF-kappa B Signaling

Alpinetin Inhibits RANKL-Induced Osteoclastogenesis and Ovariectomy-Induced Bone Loss by Modulating NFATc1 Transcription and Lysosomal Function

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss Via Suppressing Osteoclastogenesis in Mice

Virtual Screening Identified Natural Keap1-Nrf2 PPI Inhibitor Alleviates Inflammatory Osteoporosis Through Nrf2-mir214-Traf3 Axis.

A Novel Diterpenoid Suppresses Osteoclastogenesis and Promotes Osteogenesis by Inhibiting Ifrd1-Mediated and IκBα-Mediated p65 Nuclear Translocation.

Dehydrocostus lactone attenuates osteoclastogenesis and osteoclast-induced bone loss by modulating NF-κB signalling pathway.

Sophoraflavanone G Inhibits RANKL-Induced Osteoclastogenesis via MAPK/NF-κB Signaling Pathway

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

12-Deoxyphorbol 13-Acetate Inhibits RANKL-induced Osteoclastogenesis Via the Attenuation of MAPK Signaling and NFATc1 Activation

Astilbin Prevents Bone Loss in Ovariectomized Mice Through the Inhibition of RANKL‐induced Osteoclastogenesis

Lycorine Suppresses RANKL-induced Osteoclastogenesis in Vitro and Prevents Ovariectomy-Induced Osteoporosis and Titanium Particle-Induced Osteolysis in Vivo

The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.

Forsythoside B alleviates osteoarthritis through the HMGB1/TLR4/NF‐κB and Keap1/Nrf2/HO‐1 pathways

Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation

L‐tetrahydropalmatine Suppresses Osteoclastogenesis in Vivo and in Vitro Via Blocking RANK‐TRAF6 Interactions and Inhibiting NF‐κB and MAPK Pathways

Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity

18Β-Glycyrrhetinic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANKL-Mediated RANK–TRAF6 Interactions and NF-κB and MAPK Signaling Pathways

StemRegenin 1 attenuates the RANKL-induced osteoclastogenesis via inhibiting AhR- c-src-NF-κB/p-ERK MAPK-NFATc1 signaling pathway

Anemoside B4 Attenuates RANKL-induced Osteoclastogenesis by Upregulating Nrf2 and Dampens Ovariectomy-Induced Bone Loss.

IKK/NF‐κB and ROS signal axes are involved in Tenacissoside H mediated inhibitory effects on LPS‐induced inflammatory osteolysis